1. Executive Session 6:00 - 6:30
2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)
   3. DVHA Pharmacy Administration Updates 6:35 - 6:40
      - Updates
4. Medical Director Update 6:40 – 6:45
      - Clinical Programs Update
      - Prescriber Comments
5. Follow-up Items from Previous Meetings 6:45 - 7:00
      - High dose/Long term use in individual patients on diazepam
      - Amiodarone DDI recommendations
      - 2015 Retro DUR Initiatives
6. RetroDUR/DUR 7:00 – 7:00
7. Clinical Update: Drug Reviews 7:00 – 7:30
   (Public comment prior to Board action)
   Abbreviated New Drug Reviews
      - None at this time
   Full New Drug Reviews
      - Akynzeo® (netupitant & palonosetron combination)*
      - Auryxia® (ferric citrate)
      - Esbriet® (pirfenidone)
      - Mircera® (methoxy polyethylene glycol-epoetin beta)**
      - Ofev® (nintedanib)
      - Plegridy® (peginterferon beta-1a)
      - Trulicity® (dulaglutide)
      - Zavesca® (miglustat)
      - Xigduo XR® (dapagliflozin &metformin ER)
8. Therapeutic Drug Classes – Periodic Review 7:30 – 8:00
   (Public comment prior to Board action)
      - Analgesics/Anesthetics, Topical
      - Anemia: Hematopoietic/Erythropoietic Agents
      - Anti-emetics
      - Antifungals, Topical & Onychomycosis Agents
      - Dermatological Agents- Immunomodulators
      - NSAIDs & COX-2 Inhibitors
      - Scabicides & Pediculicides
      - Skeletal Muscle Relaxants
9. New Managed Therapeutic Drug Classes 8:00 – 8:00
(Public comment prior to Board action)

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:00 – 8:00
(Public comment prior to Board action)

11. General Announcements 8:00– 8:30
Selected FDA Safety Alerts

Mucinex Fast-MAX Products: Recall - Incorrect Labeling
Including certain lots of Mucinex Fast-MAX Night Time Cold & Flu; Mucinex Fast-MAX Cold & Sinus; Mucinex Fast-MAX Severe Congestion & Cough and Mucinex Fast-MAX Cold, Flu & Sore Throat

FDA issues final guidance on the evaluation and labeling of abuse-deterrent opioids
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm440713.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Counterfeit Version of Botox Found in the United States

Amyotrophic Lateral Sclerosis (ALS) Statement

12. Adjourn 8:30

* Included in Anti-emetics TCR
** Included in Anemia: Hematopoietic/Erythropoietic Agents TCR